J. Safra Sarasin Holding AG Sells 15,226 Shares of Solventum Corporation $SOLV

J. Safra Sarasin Holding AG reduced its stake in shares of Solventum Corporation (NYSE:SOLV) by 78.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 4,249 shares of the company’s stock after selling 15,226 shares during the period. J. Safra Sarasin Holding AG’s holdings in Solventum were worth $322,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. SOA Wealth Advisors LLC. lifted its holdings in shares of Solventum by 1,397.3% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 554 shares of the company’s stock worth $42,000 after acquiring an additional 517 shares during the last quarter. Chelsea Counsel Co. lifted its holdings in shares of Solventum by 720.7% during the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after acquiring an additional 9,304 shares during the last quarter. HB Wealth Management LLC lifted its holdings in shares of Solventum by 5.6% during the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock worth $263,000 after acquiring an additional 185 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Solventum by 1.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 37,696 shares of the company’s stock worth $2,859,000 after acquiring an additional 452 shares during the last quarter. Finally, V Square Quantitative Management LLC lifted its holdings in shares of Solventum by 8.9% during the 2nd quarter. V Square Quantitative Management LLC now owns 5,183 shares of the company’s stock worth $393,000 after acquiring an additional 422 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a report on Saturday, September 27th. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Tuesday, July 1st. Piper Sandler reissued an “overweight” rating and issued a $94.00 price target (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Jefferies Financial Group began coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target for the company. Finally, UBS Group began coverage on shares of Solventum in a research note on Wednesday. They issued a “neutral” rating and a $77.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $84.60.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $74.03 on Friday. The company has a market cap of $12.84 billion, a price-to-earnings ratio of 34.27, a price-to-earnings-growth ratio of 3.01 and a beta of 0.50. The company has a 50-day moving average price of $72.80 and a 200-day moving average price of $72.18. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.